Sweden Faces Crisis as Key Opioid Addiction Medication Subutex to Be Withdrawn

Sweden is confronting a critical healthcare challenge with the announcement that Subutex, a primary medication for treating opioid dependence, will be withdrawn from the Swedish market next year. This development has sent shockwaves through the addiction treatment community, stirring concerns over patient care continuity.

Subutex, administered as a monthly injection, is essential in mitigating withdrawal symptoms for individuals battling opioid addiction, especially those dependent on heroin. Its departure creates a 'nödsituation' or emergency, according to addiction specialist Joar Guterstam from the Karolinska Institute, who described the news as an 'unpleasant surprise' and warned that "this will become an emergency.”

The pharmaceutical company Indivior, responsible for supplying Subutex, has decided to cease sales in Sweden and several other European countries, shifting its focus entirely to the U.S. market. The Swedish Medical Products Agency confirmed the withdrawal but highlighted their inability to compel the company to continue the supply.

While alternatives to Subutex exist, such as daily oral medications, these require more intensive monitoring and frequent administration, complicating treatment for patients who relied on the monthly injection for stability. Guterstam emphasized the urgent need to reprioritize and rapidly test alternatives to prevent a significant gap in addiction care.

The withdrawal of Subutex threatens to destabilize Sweden's current opioid addiction treatment framework, raising serious questions about how healthcare providers will manage patient care moving forward amid limited options.

As of November 14, 2025, Swedish health authorities and addiction specialists are advocating for swift action to address this impending crisis and explore viable medication alternatives to support vulnerable patients in recovery.